A Phase II Trial of Combination Therapy With Celecoxib and Taxotere for the Treatment of Stage D3 Prostate Cancer
Status:
Unknown status
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this clinical trial is to find out the safety and effectiveness as well as
patient's quality of life on the combination of Taxotere and celecoxib on patients with
hormone refractory prostate cancer. Celecoxib (Celebrex) is an FDA approved drug to treat
arthritis. Taxotere (Docetaxel) is an FDA approved chemotherapy drug to treat certain forms
of cancer. Both drugs have demonstrated evidences of tumor blood vessel suppression and
combination of these two drugs could possibly arrest further tumor growth or make the tumor
decrease in size.